3-((5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one | 1433852-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-((5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one
• 英文别名: 3-(5-Acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one；3-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-one
• CAS: 1433852-61-9
• 化学式: C₂₀H₂₈BN₅O₄
• 分子量: 413.284
• InChiKey: YTPXWXHMXQDMES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.99
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  88.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-((5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one 、 (4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridine-3-yl)methyl acetate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 sodium acetate 作用下， 以 水 、 乙腈 为溶剂， 反应 2.0h， 以48%的产率得到(4-(5-((5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methyl acetate
  参考文献：
  名称：

  HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY

  摘要：

  公开号：

  EP2773638B1
• 作为产物：
  描述：

  1-(2-溴甲基)-5-溴甲基-3-硝基-1-氢-吡唑 在 ammonium hydroxide 、 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 氢气 、 potassium acetate 、 caesium carbonate 、 三乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 106.0h， 生成 3-((5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one
  参考文献：
  名称：

  HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY

  摘要：

  公开号：

  EP2773638B1

文献信息

• 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS
  申请人：Genentech, Inc.

  公开号：US20130116246A1

  公开（公告）日：2013-05-09

  8-Fluorophthalazin-1(2h)-one compounds of Formula II where one or two of X 1 , X 2 , and X 3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula II for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  提供了公式II的8-氟邻菲啉-1(2H)-酮化合物，其中X1、X2和X3中的一个或两个是N，包括立体异构体、互变异构体和其药用可接受盐，用于抑制Btk激酶，并用于治疗由Btk激酶介导的炎症等免疫紊乱。公开了使用公式II化合物进行哺乳动物细胞中的体外、体内和体内诊断以及治疗这类疾病或相关病理条件的方法。
• 8-fluorophthalazin-1(2H)-one compounds
  申请人：Genentech, Inc.

  公开号：US08669251B2

  公开（公告）日：2014-03-11

  8-Fluorophthalazin-1(2h)-one compounds of Formula II where one or two of X1, X2, and X3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula II for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  本发明提供了公式II中X1、X2和X3中的一个或两个为N的8-氟菲啰嗪-1（2H）-酮化合物，包括立体异构体、互变异构体和其药学上可接受的盐，用于抑制Btk激酶并治疗由Btk激酶介导的免疫紊乱，如炎症。本发明还揭示了在哺乳动物细胞中使用公式II化合物进行体外、原位和体内诊断和治疗此类疾病或相关病理条件的方法。
• HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS
  申请人：Genentech, Inc.

  公开号：US20140378432A1

  公开（公告）日：2014-12-25

  Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  提供了杂环吡啶酮和氮杂吡啶酮化合物，包括立体异构体、互变异构体和药学上可接受的盐，用于抑制Btk激酶，并治疗由Btk激酶介导的免疫紊乱，例如炎症。公开了使用杂环吡啶酮和氮杂吡啶酮化合物进行哺乳动物细胞中的体外、体内和原位诊断和治疗这种疾病或相关病理条件的方法。
• Heteroaryl pyridone and aza-pyridone compounds
  申请人：Genentech, Inc.

  公开号：US08716274B2

  公开（公告）日：2014-05-06

  Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X1, X2, and X3 are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  提供了公式I的杂环吡啶酮和氮杂吡啶酮化合物，其中X1、X2和X3中的一个或两个为N，包括立体异构体、互变异构体和药学上可接受的盐，用于抑制Btk激酶并治疗由Btk激酶介导的免疫紊乱，如炎症。公开了使用公式I化合物进行哺乳动物细胞中的体外、原位和体内诊断和治疗这种疾病或相关病理条件的方法。
• HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS
  申请人：Genentech, Inc.

  公开号：US20160228432A1

  公开（公告）日：2016-08-11

  Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  提供杂环芳基吡啶和杂环芳基氮杂吡啶化合物，包括立体异构体、互变异构体和药学上可接受的盐，用于抑制Btk激酶和治疗由Btk激酶介导的免疫紊乱，如炎症。揭示了使用杂环芳基吡啶和杂环芳基氮杂吡啶化合物在哺乳动物细胞中进行体外、体内诊断和治疗这些紊乱或相关病理条件的方法。